AbbVie

The preliminary success of a drug designed to combat idiopathic pulmonary fibrosis could give Galapagos NV (ADR) (NASDAQ: GLPG) a 10-percent boost, according to Morgan Stanley. A 23-person study of the drug GLPG1690, an autotaxin inhibitor, found that patients had better lung function than those...

Three leading biotech companies will step into the earnings spotlight this week. Consensus forecasts from Wall Street analysts call for earnings growth from just two of them. And only one of them has topped estimates by double-digits in recent quarters. While the biotechnology industry has had a...

The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...

Two of the so-called FANG stocks offered up disappointing quarterly results last week. The other two FANG stocks are on deck to share their latest results this week. Wall Street analysts continue to look for strong earnings growth from both of them. The so-called FANG stocks were the momentum...

Upcoming earnings highlights include the latest results from two automaker giants. Wall Street analysts are looking for strong earnings growth from both of them. However, estimates have been slipping for one and rising for the other. Expectations were already high for the latest earnings from...

Shares of AbbVie Inc (NYSE: ABBV) were trading higher by nearly 2 percent early Tuesday morning after the company announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval of Venclexta. Venclexta, a table taken orally, is used for the treatment of patients diagnosed...

"Biotech is booming," says LifeSci Capital co-founder and co-manager of the BioShares exchange traded funds, Andrew McDonald. McDonald, along with fellow LifeSci co-founder Paul Yook, spoke with Benzinga about innovations in biotech and how investors might take advantage. BZ: What...

This weekend in Barron's online: a special report on the best mutual fund families, an interview with a noted critic of Vladimir Putin, as well as the prospects for AbbVie, Vantiv, Actuant, Ecolab and more. Cover Story "Dressing Up 2014" by Lawrence C. Strauss. This week's...

U.S. stocks surged on Friday, lifting the Dow and S&P 500 to new all-time high record closes. Investors were treated to news of a surprise stimulus expansion from the Bank of Japan. The Japanese central bank increased its yearly target for monetary expansion to 80-trillion yen ($724 billion...

Data out on Tuesday showed that the Chinese economy grew just 7.3 percent in the third quarter, a sizable drop from the nation’s second quarter growth of 7.5 percent. The figure beat expectations, but still marks China’s slowest quarter of growth since the financial crisis and is...

U.S. stocks tumbled further on Wednesday and recovered significantly from intraday lows in a day of heavily volatility. The Dow traded lower by more than 450 points, dipping below 16,000 levels the index hasn't seen since February. The index recovered most of the losses but still closed the...

Oil prices plunged on Tuesday, posting the largest one-day decline in about two years. The sharp fall was due in large part to the International Energy Agency’s decision to trim its global demand growth forecast for this year and the next amid a growing supply glut. Though demand is...